Zulresso (Brexanolone) Patent Expiration, LOE Window & CMS Spending

Zulresso (Brexanolone) by Sage Therapeuti: FDA Orange Book LOE 2037-03-08, 0 AB generics, $456K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSage Therapeuti
FDA Application & PathwayN211371 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2037-03-08
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$456K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$456K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel